Fresenius SE & Co. (OTCMKTS:FSNUY – Get Free Report)’s share price hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as $14.75 and last traded at $14.55, with a volume of 80762 shares. The stock had previously closed at $14.13.
Wall Street Analysts Forecast Growth
Separately, Morgan Stanley reissued an “overweight” rating on shares of Fresenius SE & Co. in a research report on Wednesday, August 13th. One analyst has rated the stock with a Strong Buy rating and two have given a Buy rating to the company. According to MarketBeat, Fresenius SE & Co. presently has a consensus rating of “Buy”.
View Our Latest Stock Report on Fresenius SE & Co.
Fresenius SE & Co. Stock Performance
Fresenius SE & Co. (OTCMKTS:FSNUY – Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported $0.24 earnings per share for the quarter, topping analysts’ consensus estimates of $0.22 by $0.02. The company had revenue of $6.48 billion for the quarter, compared to analysts’ expectations of $5.83 billion. Fresenius SE & Co. had a net margin of 5.09% and a return on equity of 9.33%. Research analysts predict that Fresenius SE & Co. will post 0.79 EPS for the current fiscal year.
About Fresenius SE & Co.
Fresenius SE & Co KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.
Featured Stories
- Five stocks we like better than Fresenius SE & Co.
- Insider Buying Explained: What Investors Need to Know
- Beware The Death Cross: 3 Stocks Triggering This Spooky Signal
- 3 Monster Growth Stocks to Buy Now
- 2 Ways to Trade Qualcomm Ahead of November’s Earnings
- Growth Investing: Should You Adopt This Investing Strategy in 2022?
- Lululemon: 2 Signs the Bottom Is In, and 1 Sign It Isn’t
Receive News & Ratings for Fresenius SE & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co. and related companies with MarketBeat.com's FREE daily email newsletter.